Day: January 24, 2022

Categories : Diseases, Syndromes and ConditionsTags :

A New Method to Block Listeria Infections

On By ModernMedia
Photo by Drew Hays on Unsplash

University of Queensland researchers have unlocked a way of fighting Listeria infections, which can cause severe and potentially illness in pregnant women and immunocompromised individuals.

Listeria infection does not cause disease in most people, but can be deadly for the immunocompromised and is also a major health concern during pregnancy and can lead to miscarriage, stillbirth and premature birth.

From 2017 to 2018, South Africa suffered the world’s largest listeriosis outbreak, in which there were 216 deaths out of 1060 recorded cases.

During the study, published in the journal PLOS Pathogens, researchers discovered a way to block Listeria from making the proteins that allow bacteria to survive and multiply in immune cells. University of Queensland’s Professor Antje Blumenthal said using a small, drug-like inhibitor has improved their understanding of Listeria’s weak spot.

“Listeria is found in the soil and sometimes in raw foods. Once ingested it can hide from the immune system and multiply inside immune cells,” Prof Blumenthal said.

“Instead of killing the bacteria, the immune cells are used by the bacteria to multiply and are often killed by Listeria growing inside them.

“Our study showed the bacteria could be cleared with a small drug-like inhibitor that targets the ‘master regulator’ of the proteins that help Listeria grow in immune cells. The inhibitor helped the immune cells survive infection and kill the bacteria.”

Previously, studies into Listeria’s ‘master regulator’, which controls critical proteins that make the bacteria virulent, have mostly been based on engineered bacteria, or mutated versions of these proteins.

“By using a drug-like inhibitor, we were able to use molecular imaging and infections studies to better understand what happens to Listeria when the bacteria cannot effectively grow inside immune cells and hide from immune defence mechanisms,” Prof Blumenthal said.

“We hope that our discovery, together with recent research into the master proteins’ molecular structure and functions, could guide the development of inhibitors and new drugs to treat Listeria infection.”

“Our findings could also inform design of inhibitors against related proteins that are found in different bacteria,” Prof Blumenthal said.

Source: University of Queensland

Categories : Metabolic DisordersTags :

Simple Dietary Supplement in Type 1 Diabetes Calms Immune System

On By ModernMedia
Gut microbiome. Credit: Darryl Leja, NIH

A clinical trial performed by Australian scientists showed that a simple dietary supplement that targeted gut microbiota could improve gut health and strengthen the immune system in individuals with type 1 diabetes.

The supplement is a type 2–resistant starch consisting of a high-amylose (70%) maize starch that has been modified by bonding the acetate and butyrate. The supplement is resistant to digestion in the upper gastrointestinal tract and delivers a very high yield of short-chain fatty acids (SCFAs) in the colon. This makes it a useful tool to measure the effect of SCFAs on intestinal biology.

According to senior author and lead investigator Dr Eliana Marino, the study tested 21 adults with type 1 diabetes who incorporated the supplement into their daily diet for six weeks. Increased production of metabolites by the gut microbiota was observed, specifically SCFAs. This has an important role in preventing type 1 diabetes.

“People with 1 diabetes have shown altered gut microbiota and reduced production of short-chain fatty acids in stools and blood. We previously have demonstrated that the supplement used in this human study protected mice from diabetes,” said Dr Marino.

Published in Microbiome, the clinical trial showed that participants’ blood immune cells developed a more regulatory phenotype post-intervention.

“We were very excited to find that blood immune cells had become more regulated. Because type 1 diabetes is caused when the immune system becomes too activated and attacks the insulin-producing cells in the pancreas,” said co-lead researcher Associate Professor Hamilton-Williams.

“Type 1 diabetes is a lifelong autoimmune disease that is on the rise with no cure. Individuals living with type 1 diabetes depend on insulin treatment. As a consequence, they can develop late life-threatening inflammatory complications, such as kidney failure, neurological and cardiovascular diseases,” said co-lead researcher Associate Professor Sonia Saad

“While glucose control and insulin requirements didn’t change overall, the participants with the highest short-chain fatty acid concentrations showed the best glucose control after the supplementation,” said co-lead researcher Dr Kirstine Bell.

“Using this supplement for longer and starting it earlier in the disease could potentially stop the immune attack, preserving insulin-producing cells and improving glucose regulation,” said Dr Marino.

“This dietary supplementation represents a safe and accessible alternative therapy for many children with type 1 diabetes or other autoimmune diseases. Also, it could decrease the risk of subsequent inflammatory complications such as cardiovascular disease as clinical trials are underway,” said Dr Marino.

Source: Monash University

Categories : Lab Tests and ImagingTags :

A New Test to Diagnose Dizziness without Deafening

On By ModernMedia
Source: Miika Luotio on Unsplash

Swedish researchers have developed a new way to diagnose dizziness problems in a simpler and less painful way than the old method. A bone conduction speaker, easily attached behind the ear, can make the diagnosis more efficient and safer – especially for patients with pre-existing hearing problems.

For patients with dizziness, the relationship of dizziness and hearing is used for diagnosis. Typically, a ‘VEMP’ test (Vestibular Evoked Myogenic Potentials) is performed. With loud sounds, the test evokes a muscle reflex contraction in the neck and eye muscles, triggered by the vestibular system. In their new approach, reported in Communications Medicine, researchers at Chalmers University instead made use of bone-conducted sounds to achieve better results.

“We have developed a new type of vibrating device called B250 that is placed behind the ear of the patient during the test,” said Bo Håkansson, a professor at Chalmers University. “The vibrating device is small and compact in size and optimised to provide an adequate sound level for triggering the reflex at frequencies as low as 250 Hz, which we have found to be optimal for VEMP stimulation. Previously, no vibrating device has been available that was directly adapted for this type of test of the balance system.”

In bone conduction transmission, sound waves are transformed into vibrations through the skull, stimulating the cochlea within the ear, in the same way as when sound waves normally go through the ear canal, the eardrum and the middle ear. This can be used in various technologies such as in hearing aids.

Half of over-65s suffer from dizziness, but the causes can be difficult to diagnose for several reasons. Dizziness in 50% of those cases results from vestibular system problems. But current VEMP methods have major shortcomings and can cause hearing loss and discomfort for patients. The VEMP test uses very high sound levels which can cause permanent hearing damage. Additionally, if certain types of hearing loss are already present, the test can be inconclusive.

“The previous test was like a machine gun going off next to the ear – with this bone-conduction method it will be much more comfortable. The sound levels to which patients are exposed can be minimised. The test can be performed at 40 decibels lower than today’s method, which uses air-conducted sounds through headphones. This eliminates the risk that the test itself could cause hearing damage,” said researcher Karl-Johan Fredén Jansson, who made all the measurements in the project.

“The benefits also include safer testing for children, and that patients with impaired hearing function due to chronic ear infections or congenital malformations in the ear canal and middle ear can still be diagnosed for the origin of their dizziness,” said Prof Håkansson.

The device has now been tested and developed in several patient studies that have been published internationally, both with healthy individuals to obtain normal data, and in patients suffering from various types of dizziness. The device is compatible with standardised equipment for balance diagnostics in healthcare, which makes it easy to use. In addition to the benefits for patients, the cost of the new technology is also judged to be lower than the corresponding equipment used today.

Source: News-Medical.Net

Categories : Ethics and LawTags :

Medical Bodies Push Back against Commission for Gender Equality’s Statement

On By ModernMedia
Image source: NCI on Unsplash

The South African Medical Research Council (SAMRC), along with other professional medical and scientific institutions released a statement  distancing themselves from the Commission for Gender Equality’s (CGE) press release of 16 January, 2022, titled “Warning Against Imposing Mandatory Covid-19 Vaccination on Employees and Students”. [PDF]

The CGE cited an article published in Obstetrics and Gynaecology which found that women receiving Pfizer-BioNTech, Moderna or J&J COVID vaccines, vaccine administration was associated with less than a one-day change in cycle length for both vaccine-dose cycles compared with pre-vaccine cycles. The article concluded that clinically meaningful change in menstrual cycle duration associated with COVID vaccination was found. 

The CGE used this study as justification, cautioning businesses and institutions against mandatory vaccination and recommended against sanctions for employees who chose to remain vaccinated.

The signatories expressed their concern at the contents of the statement which is at odds with the scientific understanding of COVID vaccinations, a concern which is compounded by the “enormous influence” of the GCE.

They accept that the vaccine mandates are subject to legal scrutiny, but take issue with the commission “trying to bolster its argument by wrongly insinuating that COVID vaccination has the potential to harm women’s health.”

They also point out that the commission seems to disregard the much greater risks to women and their unborn babies of COVID infection, while misinterpreting evidence on minor menstrual cycle lengthening. This creates fear and confusion in vaccinated women, and may increase vaccine hesitancy.

“It fails to appreciate that one in six unvaccinated pregnant women admitted to hospital in South Africa with COVID infection requires mechanical ventilation, and one in 16 has a fatal outcome,” the signatories stated.

They noted that COVID vaccination provides upwards of 80% protection against severe disease, hospitalisation and death.

They endorse the view of the College of Obstetricians and Gynaecologists of South Africa, which draws on research of the highest quality, that the menstrual effects are minor.

The evidence is “indisputable” that COVID vaccination is safe, does not negatively affect women’s bodies and saves the lives of women, they stress. Statements to the contrary are strongly repudiated.

“We are of the view that the CGE, like all state institutions, medical and scientific bodies, social partners and civil society formations working in the fields of women’s rights, empowerment and equality, should urge women to get vaccinated and advance and defend their rights to all relevant information about and access to vaccination.”

The signatories call on the CGE to withdraw its 16 January statement and to share with it scientific facts on COVID vaccination and women’s health.

Source: South African Medical Research Council

Categories : Ageing Neurodegenerative DiseasesTags :

How Many Intervention Sessions to Prevent Cognitive Decline?

On By ModernMedia
Image by Mar Lezhava on Unsplash

Physical activity, diet and cognitive stimulation are all known to be good interventions for the prevention of Alzheimer’s disease and dementia. Now an international team of researchers has determined that only about a dozen intervention sessions are all that were needed to observe an improvement in cognition.

Until now, the number of sessions or “doses” needed for optimal effect has been unknown. Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study led by Université de Montréal psychology professor Sylvie Belleville showed that between 12 and 14 sessions were all that were needed to boost cognitive ability, though the gain observed levelled off with more sessions.

“In pharmacological studies, every effort is made to define an optimal treatment dose needed to observe the expected effects, “ said Prof Belleville,  a neuropsychologist and researcher at the research centre of the UdeM-affiliated Institut universitaire de gériatrie de Montréal. “This is rarely done in non-pharmacological studies, especially those on the prevention of cognitive decline, where little information is available to identify this dose.

“Defining an optimal number of treatment sessions is therefore crucial.,” she continued. “Indeed, proposing too few sessions will produce no noticeable improvement effects, but too many sessions is also undesirable as these interventions are costly. They are costly both for the individual who follows the treatments, in terms of time and involvement, and for the organisation offering these treatments.”

The study is based on a secondary analysis of data from the three-year Multidomain Alzheimer Preventive Trial (MAPT) and examined 749 participants who received a range of interventions aimed at preventing cognitive decline. These interventions included dietary advice, physical activity and cognitive stimulation.

In their research, Prof Belleville’s team noted that people’s individuality should be considered when determining the optimal treatment dose.

In their study, the researchers gauged the effects of the sessions in terms of each participant’s age, gender, education level, and cognitive and physical condition. The relationship between the “dose” each received and their cognitive improvement was then analysed.

The findings revealed an increase with dose followed by a plateau effect after 12 to 14 sessions. However, participants with lower levels of education or more risk factors for frailty did benefit from more sessions.

The researchers concluded that it’s important to pinpoint an optimal dose and to customise the treatment for each individual. Not only is “dosage” an important component of behavioural interventions, it can also provide valuable information in resource-constrained settings, helping public-health agencies develop effective prevention programs and offer guidance to older adults and clinicians.

Source: University of Montreal

Categories : Medical IndustryTags :

SA Healthcare Bolstered With Vaccine Lab Investment and Loans

On By ModernMedia
Photo by Louise Reed on Unsplash

Last week, South African healthcare received a double shot in the arm with the opening of a local vaccine manufacturing facility and the approval of a World Bank loan to bolster social safety nets and health systems.

On Wednesday, President Cyril Ramaphosa and health technology billionaire Dr Patrick Soon-Shiong officially opened a new vaccine manufacturing facility in Brackenfell, Western Cape.

The South African-born entrepreneur has been strongly supporting local healthcare, with R3 billion invested to help SA share vaccine technology with the rest of Africa. His company, ImmunityBio, is developing a T-cell based universal COVID vaccine, currently in Phase III trials in SA. The same adenovirus vector technology it uses is also being tested in cancer vaccines.

“It has been a dream of mine, since I left the country as a young physician, to bring state-of-the-art, 21st century medical care to SA and to enable the country to serve as a scientific hub for the continent,” Dr Shoon-Siong had previously said. The technology transfer will help “establish much-needed capacity and self-sufficiency.”

The hub will transfer technology, know-how and materials for DNA, RNA, adjuvant vaccine platforms and cell therapies to SA.

“There is no reason we couldn’t make 500 million doses a year,” said Dr Soon-Shiong, who is also a Wits alumnus. “Subject to the raw material being available.”

He said he wants to tap the country’s expertise on prevalent diseases such as HIV and cervical cancer. “There are fantastic scientists with deep knowledge about these diseases,” he said. “More so than in America because they see these patients every day.”

President Ramaphosa and Dr Soon-Shiong also launched the Coalition to Accelerate Africa’s Access to Advanced Healthcare, which aims to drive the development of innovative therapeutics and ensure the continent is prepared for future pandemics.

The coalition aims to manufacture a billion doses of the COVID vaccine by 2025 and to develop treatments for conditions including cancer, COVID, tuberculosis and HIV.

South Africa also received approval from the World Bank for a US$750 million COVID relief loan aimed at reducing the worst of the pandemic’s impact on the poor.

“The World Bank budget support is coming at a critical time for us and will contribute towards addressing the financing gap stemming from additional spending in response to the COVID crisis,” said Dondo Mogajane, Director General of the National Treasury. “It will assist in addressing the immediate challenge of financing critical health and social safety net programs whilst also continuing to develop our economic reform agenda to build back better.”

Meanwhile, Health Minister Dr Joe Phaahla warned that South Africa will likely enter a fifth wave when cold temperatures in May, though what COVID variants may drive it remain to be seen.